文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性非小细胞肺癌患者18FDG PET显示的免疫治疗诱导器官炎症的预后价值

Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-14

本研究基于两项前瞻性试验中IIIB/IV期非小细胞肺癌(NSCLC)患者数据,评估免疫检查点抑制剂(ICPI)治疗期间18FDG PET所见的免疫诱导器官炎症的预后价值。探索队列(法国尼斯)中PETInterim1和PETInterim2显示72.8%患者出现至少一种ICPI诱导器官炎症,iPERCIST肿瘤缓解及免疫诱导胃炎均与总生存改善相关;验证队列(意大利热那亚)中免疫诱导胃炎(19.6%)与总生存改善相关(p=0.04)。结论认为早期中期18FDG PET显示的免疫诱导胃炎是可重复的改善总生存的影像生物标志物。

要点

  • 早期中期18FDG PET可在约20%的ICPI治疗NSCLC患者中显示免疫诱导胃炎。
  • 免疫诱导胃炎与总生存改善相关,在探索队列和验证队列中均得到验证。
  • iPERCIST肿瘤缓解与无进展生存改善相关,并与胃炎联合构建的模型可预测2年总生存。

核心结论

  • 早期中期18FDG PET显示的免疫诱导胃炎是ICPI治疗的NSCLC患者总生存改善的新颖且可重复的影像生物标志物。

研究设计与样本

  • 分析两项前瞻性试验中纳入的IIIB/IV期NSCLC患者数据,在基线、治疗7-8周后(PETInterim1)和12-16周后(PETInterim2)行18FDG PET/CT,采用iPERCIST评估肿瘤缓解,并收集 deemed 由ICPI相关器官炎症所致的异常器官18FDG摄取。
  • 探索队列来自法国尼斯,验证队列来自意大利热那亚。

主要发现

  • 探索队列中PETInterim1和PETInterim2显示72.8%患者出现至少一种ICPI诱导器官炎症,包括中肠/后肠炎症33.7%、胃炎21.7%、甲状腺炎18.5%、肺炎17.4%和其他器官炎症9.8%。
  • 探索队列中iPERCIST肿瘤缓解与无进展生存改善相关(p < 0.001),iPERCIST肿瘤缓解和PET评估的免疫诱导胃炎均与总生存改善相关(p < 0.001和p = 0.032)。
  • 联合上述两个独立变量构建的模型预测2年总生存的敏感性为80.3%、特异性为69.2%(AUC = 72.7)。
  • 验证队列中免疫诱导胃炎见于19.6%患者,与总生存改善相关(p = 0.04);该模型预测2年总生存的敏感性和特异性分别为72.0%和63.6%(AUC = 70.7),预测3年总生存的敏感性和特异性分别为69.2%和80.0%(AUC = 78.2)。

关键数值与推荐

  • 探索队列:ICPI诱导器官炎症发生率72.8%,其中中肠/后肠炎症33.7%、胃炎21.7%、甲状腺炎18.5%、肺炎17.4%、其他器官炎症9.8%。
  • 验证队列:免疫诱导胃炎发生率19.6%,与总生存改善相关(p = 0.04)。
  • 探索队列模型预测2年总生存:敏感性80.3%,特异性69.2%,AUC = 72.7。
  • 验证队列模型预测2年总生存:敏感性72.0%,特异性63.6%,AUC = 70.7;预测3年总生存:敏感性69.2%,特异性80.0%,AUC = 78.2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the prognostic value of immunotherapy-induced organ inflammation observed on 18FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). METHODS: Data from patients with IIIB/IV NSCLC included in two different prospective trials were analyzed. 18FDG PET/CT exams were performed at baseline (PETBaseline) and repeated after 7-8 weeks (PETInterim1) and 12-16 weeks (PETInterim2) of treatment, using iPERCIST for tumor response evaluation. The occurrence of abnormal organ 18FDG uptake, deemed to be due to ICPI-related organ inflammation, was collected. RESULTS: Exploratory cohort (Nice, France): PETInterim1 and PETInterim2 revealed the occurrence of at least one ICPI-induced organ inflammation in 72.8% of patients, including midgut/hindgut inflammation (33.7%), gastritis (21.7%), thyroiditis (18.5%), pneumonitis (17.4%), and other organ inflammations (9.8%). iPERCIST tumor response was associated with improved progression-free survival (p < 0.001). iPERCIST tumor response and immuno-induced gastritis assessed on PET were both associated with improved overall survival (OS) (p < 0.001 and p = 0.032). Combining these two independent variables, we built a model predicting patients' 2-year OS with a sensitivity of 80.3% and a specificity of 69.2% (AUC = 72.7). Validation cohort (Genova, Italy): Immuno-induced gastritis (19.6% of patients) was associated with improved OS (p = 0.04). The model built previously predicted 2-year OS with a sensitivity and specificity of 72.0% and 63.6% (AUC = 70.7) and 3-year OS with a sensitivity and specificity of 69.2% and 80.0% (AUC = 78.2). CONCLUSION: Immuno-induced gastritis revealed by early interim 18FDG PET in around 20% of patients with NSCLC treated with ICPI is a novel and reproducible imaging biomarker of improved OS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Humbert O, Bauckneht M, Gal J, et al. Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35562529. doi:10.1007/s00259-022-05788-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。